Skip to main content

Chlordiazepoxide / methscopolamine Pregnancy and Breastfeeding Warnings

Chlordiazepoxide / methscopolamine Pregnancy Warnings

Chlordiazepoxide-methscopolamine has been assigned to pregnancy category C by the FDA. Chlordiazepoxide crosses the placenta and achieves a maternal:fetal plasma ratio of 1:1. An increased risk of congenital malformations in humans has been associated with the use of chlordiazepoxide in pregnancy, particularly in the first and second trimesters. Chronic use of chlordiazepoxide in later pregnancy has been associated with neonatal withdrawal and a "floppy infant syndrome" consisting of hypotonia, depression, decreased responsiveness, and reluctance to feed. There are no controlled data in human pregnancy. Chlordiazepoxide-methscopolamine is only recommended for use during pregnancy when benefit outweighs risk.

See references

Chlordiazepoxide / methscopolamine Breastfeeding Warnings

There are no data on the excretion of chlordiazepoxide-methscopolamine into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Librax (chlordiazepoxide-methscopolamine)." Victory Pharma (2004):

References for breastfeeding information

  1. "Product Information. Librax (chlordiazepoxide-methscopolamine)." Victory Pharma (2004):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.